Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 4236921

Next Previous
Drug Profile

PF 4236921

Alternative Names: PF-04236921; PF-4236921

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • Discontinued Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 01 Mar 2016 Pfizer completes the ANDANTE II trial for Crohn's disease in USA, Canada, Brazil, the UK, Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Sweden, Switzerland, Australia, New Zealand and Israel (NCT01345318)
  • 28 Oct 2015 Discontinued - Phase-II for Systemic lupus erythematosus in USA, Romania, Puerto Rico, Poland, Peru, Moldova, South Korea, Colombia, Chile, Argentina, Taiwan, Germany and Hungary (SC)
  • 17 Jun 2015 Phase-II development is ongoing for Crohn's disease and Systemic lupus erythematosus in World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top